These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1391268)

  • 1. Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation.
    Egberts J
    Biol Neonate; 1992; 61 Suppl 1():59-65. PubMed ID: 1391268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention and treatment of respiratory distress syndrome in premature infants using intratracheally administered surfactants].
    de Winter JP; Egberts J; de Kleine MJ; van Bel F; Wijnands JB; Guit GL
    Ned Tijdschr Geneeskd; 1992 Oct; 136(41):2018-24. PubMed ID: 1407193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical changes in neonatal hospitalisation costs after the introduction of porcine-derived lung surfactant ('Curosurf').
    Egberts J
    Pharmacoeconomics; 1995 Oct; 8(4):324-42. PubMed ID: 10155674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of antenatal corticosteroids according to maternal and perinatal factors: a retrospective cohort study.
    Claire L; Vieux R
    Am J Perinatol; 2015 Sep; 32(11):1070-7. PubMed ID: 25825960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of surfactant replacement in preterm babies.
    Mugford M; Howard S
    Pharmacoeconomics; 1993 May; 3(5):362-73. PubMed ID: 10146887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
    Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
    N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost implications of different approaches to the prevention of respiratory distress syndrome.
    Mugford M; Piercy J; Chalmers I
    Arch Dis Child; 1991 Jul; 66(7 Spec No):757-64. PubMed ID: 1863120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants.
    Jobe AH; Mitchell BR; Gunkel JH
    Am J Obstet Gynecol; 1993 Feb; 168(2):508-13. PubMed ID: 8438919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preterm birth: a cost benefit analysis.
    Rushing S; Ment LR
    Semin Perinatol; 2004 Dec; 28(6):444-50. PubMed ID: 15693401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of surfactant administration in neonates with respiratory distress syndrome. III. The role of intra-uterine stimulation on lung maturity].
    Gadzinowski J; Halliday H; Szymankiewicz M; Breborowicz G; Sackey S; Sobczak E
    Ginekol Pol; 1993 Feb; 64(2):74-7. PubMed ID: 8359730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
    Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choosing a right surfactant for respiratory distress syndrome treatment.
    Ramanathan R
    Neonatology; 2009; 95(1):1-5. PubMed ID: 18832858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surfactant therapy: past, present and future.
    Speer CP; Sweet DG; Halliday HL
    Early Hum Dev; 2013 Jun; 89 Suppl 1():S22-4. PubMed ID: 23809343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal-derived surfactant treatment of respiratory distress syndrome in premature neonates: a review.
    Fujii AM; Carillo M
    Drugs Today (Barc); 2009 Sep; 45(9):697-709. PubMed ID: 19956811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gestational effect of antenatal corticosteroids on respiratory distress syndrome in very low birth weight infants: A population-based study.
    Liu SY; Yang HI; Chen CY; Chou HC; Hsieh WS; Tsou KI; Tsao PN;
    J Formos Med Assoc; 2020 Aug; 119(8):1267-1273. PubMed ID: 31761503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial.
    Hascoët JM; Picaud JC; Ligi I; Blanc T; Moreau F; Pinturier MF; Zupan V; Guilhoto I; Hamon IR; Alexandre C; Bouissou A; Storme L; Patkai J; Pomedio M; Rouabah M; Coletto L; Vieux R
    JAMA Pediatr; 2016 Apr; 170(4):365-72. PubMed ID: 26928567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial.
    Tubman TR; Halliday HL; Normand C
    BMJ; 1990 Oct; 301(6756):842-5. PubMed ID: 2126475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of prevention and treatment of neonatal respiratory distress (RDS) with exogenous surfactant: what has changed in the last three decades?
    Mugford M
    Early Hum Dev; 2006 Feb; 82(2):105-15. PubMed ID: 16457971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.